» Articles » PMID: 38001941

Iron Bioavailability in the Extracellular Environment Is More Relevant Than the Intracellular One in Viability and Gene Expression: A Lesson from Oligodendroglioma Cells

Overview
Journal Biomedicines
Date 2023 Nov 25
PMID 38001941
Authors
Affiliations
Soon will be listed here.
Abstract

Oligodendroglioma (OG) is a brain tumor that contributes to <1% of brain tumor diagnoses in the pediatric population. Unfortunately, pediatric OG remains without definitive molecular characteristics to aid in diagnosis, and little is known about the tumor microenvironment. Tumor cells' metabolism and proliferation rate are generally higher than those of healthy cells, so their iron demand is also significantly higher. This consideration underlines the great importance of iron for tumor development and progression. In this context, this study aims to evaluate the effect of iron in a cellular in vitro model of human oligodendroglioma brain tumor. Cell morphology, the effect of siderotic medium on cell growth, iron uptake, and the expression of iron-metabolism-related genes were evaluated via optic microscopy, ICP-MS, confocal microscopy, and real-time PCR, respectively. This study underlines the great importance of iron for tumor development and progression and also the possibility of reducing the available iron concentration to determine an antiproliferative effect on OG. Therefore, every attempt can be promising to defeat OG for which there are currently no long-term curative therapies.

References
1.
Finazzi D, Arosio P . Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch Toxicol. 2014; 88(10):1787-802. DOI: 10.1007/s00204-014-1329-0. View

2.
Richardson D, Tran E, Ponka P . The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 1995; 86(11):4295-306. View

3.
Liu H, Li W, Chen Z, Zhou M, Zhuang Z, Zhang D . Increased expression of ferritin in cerebral cortex after human traumatic brain injury. Neurol Sci. 2012; 34(7):1173-80. DOI: 10.1007/s10072-012-1214-7. View

4.
Gao J, Richardson D . The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood. 2001; 98(3):842-50. DOI: 10.1182/blood.v98.3.842. View

5.
Legendre C, Garcion E . Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies. Trends Endocrinol Metab. 2015; 26(6):322-31. DOI: 10.1016/j.tem.2015.03.008. View